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Cilostazol minimizes venous ischemic injury in
diabetic and normal rats
Daisuke Wajima, Mitsutoshi Nakamura, Kaoru Horiuchi, Yasuhiro Takeshima,
Fumihiko Nishimura and Hiroyuki Nakase
Department of Neurosurgery, Nara Medical University School of Medicine, Nara, Japan
We evaluated the effects of cilostazol on venous infarction produced by a photothrombotic two-vein
occlusion (2VO) model in diabetic and control rats. The cerebral blood flow (CBF) between the
occluded veins was measured by laser Doppler flowmetry for 4hours after 2VO. Infarct size and
immunohistochemistry were evaluated 24, 48, 96, and 168hours after 2VO. Cilostazol was
administered 1hour after 2VO, and thereafter at a continuous oral dose of 60mg/kg per day.
Cilostazol reduced the infarct size, and the number of terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate nick-end labeling (TUNEL)-positive apoptotic and B-cell
lymphoma 2-associated X protein (Bax)-positive cells, and improved the CBF in control rats. In
diabetic rats, cilostazol reduced the infarct size, and the number of TUNEL-positive apoptotic and
Bax-positive cells, 96 and 168hours after 2VO, but did not improve the CBF 4hours after 2VO.
Cilostazol increased the number of B-cell lymphoma 2 (Bcl-2)-positive cells in both strains 48, 96,
and 168hours after 2VO, but did not improve vessel wall thickness or collagen deposits. Cilostazol
appeared to limit venous infarcts by improving the penumbral CBF in nondiabetic rats, and inhibited
pro-apoptotic changes through Bcl-2 overexpression, without improving the CBF in diabetic rats.
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Introduction
Cilostazol is a selective inhibitor of phosphodiester-
ase-3, which acts as an antiplatelet drug and a
vasodilator. It has been used for the treatment of
ischemic symptoms in patients with chronic periph-
eral arterial obstruction, and for the secondary
prevention of brain infarction. Recently, cilostazol
was shown to be a more effective and safer
alternative to aspirin for the long-term prevention
of secondary stroke in chronic ischemic stroke
patients (Shinohara et al, 2010). Furthermore, cilos-
tazol attenuated acute brain infarction induced by
middle cerebral artery occlusion-reperfusion
(MCAO-R) in rats, suggesting that it might have the
potential to ameliorate acute ischemic stroke by
minimizing evolving ischemic injury (Ito et al,
2009). However, the effect of cilostazol on venous
infarction remains unknown, especially in the
diabetic state.
Epidemiological studies have showed that diabetes
is a risk factor for the development of ischemic
cerebrovascular disease (Whisnant, 1997). Diabetes
is associated with a series of vascular alterations,
including intracranial atheroma, microangiopathy,
cerebrovascular atherosclerosis, rheological abnorm-
alities, and endothelial changes, any or all of which
are predisposing factors for cerebral infarction (Vinik
and Flemmer, 2002). The morbidity and mortality
associated with diabetes have traditionally been
attributed to the chronic complications affecting
both the large vessels, with an increased risk of
myocardial infarction and stroke, and the microvas-
culature of the kidneys, retinas, and peripheral
nerves. Recently, we showed that the volume of the
cerebral cortex affected by venous infarction was
increased in diabetic rats, and we also observed
significantly reduced cerebral blood flow (CBF)
90minutes after venous infarction, coupled with
increased apoptosis in and around ischemic lesions.
Morphologically, diabetic rats showed marked thick-
ening of the walls of the small cerebral vessels along
with perivascular fibrosis, indicating more severe
cerebral microvascular atherosclerotic changes than
those observed in their nondiabetic counterparts
(Wajima et al, 2010).
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www.jcbfm.comTwo-vein occlusion (2VO) provides a unique and
reliable model of cerebral venous-circulation distur-
bance involving the photochemically induced occlu-
sion of two adjacent cortical veins in the rat brain, in
which endothelial alteration stimulates platelet
activation resulting in a venous thrombus (Nakase
et al, 1996). The 2VO model causes a relatively
widespread reduction of cortical flow and the
development of small infarcts. It mimics conditions
similar to those expected to occur in an ischemic
penumbra zone, and has distinct advantages over
other arterial occlusion models (Nishioka et al,
2006). Here, we used the 2VO model to examine
the effect of cilostazol in minimizing evolving
ischemic injury in both nondiabetic and diabetic
rats.
Materials and methods
Animal Preparation
Male 4-week-old spontaneously diabetic Otsuka Long-
Evans Tokushima Fatty (OLETF) rats and control Long-
Evans Tokushima Otsuka (LETO) rats were supplied by the
Tokushima Research Institute (Otsuka Pharmaceutical,
Tokushima, Japan). In total, 40 OLETF and 40 LETO rats
were maintained in a temperature-controlled room at
23±21C with 55±15% humidity and a 12-hours light/
dark cycle. The animals were provided standard rat chow
and tap water ad libitum, and were housed under
husbandry standards that were in accordance with the
ethical guidelines of our institution. The experimental
protocol was approved by the Animal Welfare Committee
of Nara Medical University, Japan, and was conducted in
compliance with the Animal Experiment Guidelines
approved by the 89th General Assembly of the Japan
Science Council in 1980.
An oral glucose-tolerance test was performed on each rat
at 30 weeks of age to determine the diabetic status. After
16-hours fast, an oral glucose load of 2g/kg was delivered
to each rat via gavage. Blood glucose levels were measured
before gavage, and at 30, 60, 90, and 120minutes after
glucose loading, using a standard skin-prick blood gluc-
ometer (Medi-safe Mini; TERUMO, Tokyo, Japan). Animals
were classified as diabetic if the peak plasma glucose level
was >300mg/dL and if the measurement remained at
>200mg/dL for 120minutes (Kawano et al, 1992).
Anesthesia
After the diabetic status had been determined, each rat was
sedated with 1mg atropine and initially anesthetized by an
intraperitoneal injection of chloral hydrate at 36mg/100g
body weight. Tracheal intubation was performed after
relaxation, and ventilation was controlled by a small
animal respirator (Harvard Model 683; Harvard Apparatus,
MA, USA). The rats were then anesthetized with halothane
(2% for induction and 1% for maintenance) in a mixture of
70% nitrous oxide and 30% oxygen. The rectal tempera-
ture was maintained at 371C with a feedback heating pad
(CMA 150; Carnegie Medicine AB, Stockholm, Sweden).
Polyethylene catheters were inserted into the tail artery
and the left femoral vein. Blood gas parameters, including
the partial pressure of oxygen (PaO2) and the partial
pressure of carbon dioxide (PaCO2), as well as the arterial
pH, blood pressure, and glucose concentration, were
continuously monitored through the intraarterial catheter
connected to a pressure transducer (ABL 550; Radiometer,
Copenhagen, Denmark), while the venous line was used to
administer fluids and drugs.
Craniotomy
The anesthetized rats were secured in stereotactic frames
(SR-6; Narishige Inc., Tokyo, Japan) for the duration of the
experiment. After performing a 1.5-cm midline skin
incision, we prepared a left fronto-parietal cranial window
using a high-speed drill for access to the brain surface. The
entire procedure was performed with the aid of an
operating microscope (Carl Zeiss, Oberkochen, Germany).
During the craniotomy, the drill tip was cooled continu-
ously with physiological saline to avoid thermal injury to
the cortex. The dura mater was left intact. As a control, we
performed three sham operations without inducing photo-
chemical thrombosis, and were able to confirm that the
intact brain showed no notable changes compared with the
nonoccluded side in the animals with induced thrombosis.
Cortical Vein Occlusion by Photochemically Induced
Thrombosis and Medication
We performed 2VO according to the method described in
previous reports (Kimura et al 2005; Nakagawa et al, 2005;
Nakase et al, 1996; Nishioka et al, 2006; Otsuka et al, 2000;
Wajima et al, 2010). Briefly, we occluded two adjacent
cortical veins using a rose bengal dye injection (Katayama
Chemicals, Osaka City, Japan), followed by illumination by
the L4887 fiber-optic system (6,500 to 7,500lux, 540nm;
Hamamatsu Photonics, Hamamatsu, Japan) with a 100-mm
fiber. The rose bengal dye (50mg/kg) was injected slowly
into the first selected cortical vein to avoid affecting the
systemic arterial pressure, followed by exposure to light for
10minutes with the aid of a micromanipulator-assisted
light guide. Care was taken to avoid any illumination of the
tissue and vessels near the target vein. To occlude the
second selected vein, rose bengal dye (25mg/kg) was
injected intravenously followed by illumination as de-
scribed above (Nakase et al, 1996). The regional CBF was
measured, using a laser Doppler flowmeter (ALF21;
Advance, Inc., Tokyo, Japan) with a 0.8-mm needle probe,
at 25 locations within the occluded veins lateral to the
scanning field, and the mean value was calculated. The
CBF was measured before the 2VO and then at 30-minutes
intervals until 4hours after the intervention. We adminis-
tered the drug 60minutes after 2VO. Rats were orally
administered either cilostazol (60mg/kg per day) or 0.5%
carboxymethyl cellulose (CMC) sodium salt vehicle alone
as a control. After the closure of the incisions, the rats were
returned to their individual cages with free access to food
and water, and they continued to receive medication once
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study of the MCAO model in rats (Lee et al, 2008).
Histopathology
At 24, 48, 96, and 168hours after 2VO, rats were killed after
being anesthetized by an intraperitoneal injection of
chloral hydrate, followed by perfusion fixation initiated
by the transcardiac infusion of saline followed by 10%
formaldehyde. The brains were excised and coronal blocks
from the middle frontal cortex tissue, containing the two
occluded cortical cerebral veins, were paraffin processed.
Sections with a thickness of 5mm were cut and stained
with hematoxylin and eosin for examining the overall
morphology. Additional sections were cut for Van Gieson’s
elastic and immunohistochemical staining, and serial
sections were prepared for terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate nick-end
labeling (TUNEL).
Calculation of the Infarct Ratio
The infarct area was measured in brain slices by quanti-
tative histomorphometry in a blinded manner. The infarct
and hemispheric areas of each section were traced and
measured by an image-analysis system using a Windows
computer accessing the public domain National Institutes
of Health Image program, Scion Image. The percentage of
infarct area (the infarct ratio) was calculated by dividing
the infarct area by the total area of the ipsilateral hemi-
sphere. The infarct area was evaluated in serial sections at
200-mm steps. The infarct volume was calculated as the
sum of these areas and was expressed as the infarct ratio.
Van Gieson’s Elastic Staining
Brain sections were subjected to Van Gieson’s elastic
staining to examine the peri-vascular collagen deposition.
Vessel cross-sections with a long axis to short axis ratio of
<1:3 were used for evaluation and quantitative scoring,
based on our previous study of the vessels of diabetic rats
(Wajima et al, 2010). Peri-vascular fibrosis was assessed by
the ratio of vascular collagen to the total vessel area (the
area of collagen deposition/the total vessel area), in which
the total vessel area was defined as the sum of the tunica
media and the vessel lumen.
Immunohistochemistry
For the immunohistochemical analysis, unstained sections
of the cerebral cortex were deparaffinized and heated in
citrate buffer for 5minutes at 1201C in an autoclave.
Endogenous peroxidase activity was blocked by incubation
in 0.3% hydrogen peroxide (H2O2), and the sections were
incubated overnight with mouse monoclonal antibodies
directed against smooth muscle actin (SMA; Santa Cruz
Biochemicals, Santa Cruz, CA, USA; 1:100 dilution), B-cell
lymphoma 2-associated X protein (Bax; SC7480; Santa
Cruz Biochemicals; 1:500 dilution), B-cell lymphoma 2
(Bcl-2; SC7480; Santa Cruz Biochemicals; 1:300 dilution),
and advanced glycation end products (AGEs; 6D12;
TransGenic Inc., Kumamoto, Japan; 1:20 dilution).
The vascular cross-sections in the SMA-stained slides
were quantitatively analyzed, and the ratio of the tunica
media to the lumen (wall area/luminal area) was calculated
as an index of wall thickening. The percentages of Bax- and
Bcl-2-immunopositive cells within the penumbral lesions
in the ischemic cerebral tissues, and of AGE-immuno-
positive cells within the nonischemic cerebral tissues,
were estimated from the average number of cells in three
sections per rat within a 5-mm
2 area of the cortex.
Terminal Deoxynucleotidyl Transferase-Mediated
Deoxyuridine Triphosphate Nick-End Labeling
Staining
The DNA-fragmentation characteristics of cells undergoing
apoptosis were assessed by the TUNEL method in
accordance with the instructions for the ApopTag kit
(Oncor, Inc., Gaithersburg, MD, USA) with minor mod-
ifications. Briefly, after deparaffinization and rehydration,
serial sections were digested with 20mg/mL proteinase K
(Sigma, St Louis, MO, USA) for 15minutes at room
temperature, followed by exposure to terminal deoxynu-
cleotidyl transferase (Nichirei, Tokyo, Japan) in a reaction
buffer containing fixed concentrations of digoxigenin-
labeled nucleotides at 371C for 1hour. The slides were
then placed in a stop/wash buffer for 10minutes, and
subsequently incubated with antidigoxigenin-labeled per-
oxidase for 30minutes and counterstained with hemato-
xylin. Diaminobenzidine-stained cells were identified as
TUNEL positive.
The percentages of TUNEL-positive cells within these
penumbral areas were estimated using the mean number of
TUNEL-positive cells in three sections per rat within a
5-mm
2 area of the cortex, using the method described
above for Bax/Bcl-2 immunohistochemistry.
Statistical Analysis
All data are expressed as the mean±s.e.m. Statistical
significance (at P<0.05) was assessed using the Student–
Newman–Keuls test with repeated-measures analysis of
variance for data on CBF and physiological parameters,
with two-way analysis of variance for data on vessel wall
histopathology, and with one-way analysis of variance for
all other data. All statistical analyses were performed by
Sigma-Stat software (Jandel Scientific, San Rafael, CA,
USA).
Results
Body Weight and Oral Glucose-Tolerance Test
At 30 weeks of age, the 40 OLETF rats were
significantly heavier than the 40 LETO rats
(587±12 versus 352±15g, respectively; P<0.01).
The oral glucose-tolerance test revealed significantly
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compared with the LETO rats (114.6±4.1 versus
75.4±4.1mg/dL, respectively; P<0.05), as well as
significant increases in the peak glucose response
(326.5±11.3 versus 141.2±6.1mg/dL, respectively;
P<0.01). Moreover, the glucose levels remained
significantly higher in the OLETF rats than in the
LETO rats at 120minutes after administration
(254.4±3.2 versus 122.1±4.6mg/dL, respectively;
P<0.05). In light of previous findings (Kawano et al,
1992), this indicates that OLETF rats are diabetic by
30 weeks of age, whereas the glucose levels of LETO
rats remain within the normal range.
Sequential Changes in Regional Cerebral Blood Flow
The sequential changes in the regional CBF of the
OLETF rats during 2VO are shown in Figure 1.
Before 2VO, the regional CBF between the two
occluded veins was similar in the LETO and OLETF
rats (31.7±0.8 versus 31.6±0.8 laser Doppler units,
respectively). The CBF was subsequently calculated
and expressed as a percentage of the initial value (%
baseline). The CBF decreased over time in the
cilostazol-administered and vehicle-administered
OLETF rats (71.0±2.7% versus 70.2±1.8% at
30minutes after 2VO and 12.2±2.6 versus
9.5±2.7% at 240minutes, respectively). Similarly,
the CBF decreased in both the cilostazol-adminis-
tered and the vehicle-administered LETO rats until
90minutes after 2VO (71.0±1.8% versus 71.2±2.1%
at 30minutes and 35.7±2.4% versus 35.2±1.9% at
90minutes, respectively). However, compared with
the control LETO rats, cilostazol inhibited the
reduction of the CBF in the LETO rats at 120minutes
(31.3±2.8% versus 35.4±3.6%, P<0.05) and
240minutes (28.5±2.3% versus 42.1±2.8%,
P<0.05) after its administration, respectively.
Physiological Parameters
There were no significant differences between the
two groups in the mean arterial blood pressure, pH,
PaO2,P a CO2, and hematocrit (Ht) values either before
or after 2VO; however, the blood glucose concentra-
tions were significantly higher in the OLETF rats
than in the LETO rats at 240minutes after 2VO
(Table 1). The physiological parameters (other than
the glucose concentration) measured before 2VO,
and every 30minutes until 4hours after 2VO, did not
significantly differ between the strains (Table 1).
Histology, Immunohistochemistry, and Terminal
Deoxynucleotidyl Transferase-Mediated Deoxyuridine
Triphosphate Nick-End Labeling Staining
Based on the histopathological findings, lesions in
which the cells were reduced in number or were
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Figure 1 Comparison of rates of regional cerebral blood flow (CBF) in the ischemic areas of Otsuka Long-Evans Tokushima Fatty
(OLETF) and Long-Evans Tokushima Otsuka (LETO) rats. Before two-vein occlusion (2VO), the regional CBF between the two
occluded veins of the LETO and OLETF rats was similar (31.7±0.8 versus 31.6±0.8 laser Doppler units (LDU), respectively). The
CBF decreased over time in the OLETFrats. The CBFalso decreased in both the cilostazol (CZL)-administered and the carboxymethyl
cellulose (CMC)-administered groups until 90minutes after 2VO; however, CZL inhibited the reduction of CBF at 1hour after
administration in the LETO rats. The CBF, which was calculated as the average value of those in 25 points in the ischemic lesion, is
expressed as a percentage of the baseline value (% baseline). The points of occlusion and the locations of the regional CBF
measurements by the laser Doppler flowmeter are shown in the lower right of the figure.
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lesions around the infarct core were identified as so-
called penumbra. As shown in Figures 2 and 3, the
venous infarct volume increased over time and was
reduced by cilostazol in each of the five LETO rats
tested (2.5±0.4% versus 1.4±0.3% at 24hours after
2VO, 3.5±0.3% versus 2.2±0.6% at 48hours,
5.1±0.3% versus 3.5±0.5% at 96hours, and
5.5±0.6% versus 3.7±0.4% at 168hours, respec-
tively). Additionally, the infarct volume was in-
creased in both treatment groups at 24hours
(8.2±0.3% versus 7.1±0.5%) and 48hours
(10.1±0.6% versus 9.5±0.3%) after 2VO in OLETF
rats; however, cilostazol significantly reduced the
Table 1 Physiological data
MABP (mmHg) PaO2 (mmHg) PaCO2 (mmHg) pH Ht (%) Glucose (mg/dL)
LETO
Pre 2VO 108.6±6.8 125.1±7.5 42.9±2.7 7.38±0.04 45.1±0.6 78.4±4.3
30minutes after 2VO 110.4±4.9 120.1±3.5 41.7±1.8 7.37±0.09 45.3±1.1 85.4±2.4
60minutes after 2VO 111.6±6.4 122.3±6.2 42.3±2.1 7.39±0.11 45.8±0.7 79.2±3.1
90minutes after 2VO 110.4±3.5 123.1±5.4 41.1±1.5 7.41±0.14 45.2±0.6 88.4±2.4
2hours after 2VO 109.2±5.3 121.8±6.2 42.6±1.2 7.36±0.12 45.8±1.2 75.9±2.9
4hours after 2VO 107.2±5.9 124.0±8.5 42.9±2.1 7.37±0.27 45.3±0.6 83.2±5.3
OLETF
Pre 2VO 112.6±5.5 124.1±3.5 43.8±3.1 7.41±0.07 44.8±1.1 318.4±6.3
*
30minutes after 2VO 111.2±3.8 122.0±4.2 43.9±3.4 7.40±0.14 44.7±0.9 342.0±3.3
*
60minutes after 2VO 112.2±4.1 125.0±2.3 43.1±4.1 7.39±0.21 44.3±0.6 328.2±5.3
*
90minutes after 2VO 111.3±4.8 123.1±2.5 43.3±2.7 7.39±0.15 44.8±0.7 326.4±5.3
*
2hours after 2VO 110.6±3.7 125.1±4.2 43.2±1.9 7.41±0.24 44.4±0.6 331.4±4.2
*
4hours after 2VO 114.5±4.3 124.1±4.5 44.0±1.7 7.38±0.54 44.8±0.6 342.4±6.3
*
2VO, two-vein occlusion; MABP , mean arterial blood pressure; PaO2, partial pressure of oxygen; PaCO2, partial pressure of carbon dioxide; Ht, hematocrit;
OLETF, Otsuka Long-Evans Tokushima Fatty; LETO, Long-Evans Tokushima Otsuka.
All data are expressed as the mean±s.e.m. Glucose concentrations were significantly higher in OLETF rats both before and after experimental venous occlusion
(
*P<0.01). No other measures differed significantly between the two strains.
Figure 2 Hematoxylin and eosin (H&E) staining for cerebral damage induced by two-vein occlusion (2VO), and the effects of
cilostazol (CZL) and carboxymethyl cellulose (CMC) in Long-Evans Tokushima Otsuka (LETO) and Otsuka Long-Evans Tokushima
Fatty (OLETF) rats. The infarct cores, surrounded by penumbral zones, show morphological changes in the neurons (bar=500mm,
40 magnification).
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10.8±0.6%) and 168hours (13.7±0.6% versus
11.3±0.5%), respectively. Hematoxylin and eosin
staining revealed morphological changes in neurons
in both the infarct cores and the surrounding
penumbral areas. Furthermore, cells near to the
penumbra showed histological morphological signs
of apoptosis (such as nuclear pyknosis, chromatin
condensation or fragmentation, and cytoplasmic
shrinkage).
Vascular wall thickening and perivascular fibrosis,
which are signs of atherosclerosis, were more notable
in the OLETF rats than in the LETO rats. The relative
thickness of the tunica media in the small cortical
vessel walls of OLETF and LETO rats was high-
lighted by SMA staining. As illustrated in Figure 4,
the ratio of the wall thickness to the luminal area was
significantly higher in the OLETF rats than in the
LETO rats. The wall thickness was not improved by
cilostazol at 168hours after 2VO in either the LETO
rats (43.3±1.2% versus 42.4±1.4%) or the OLETF
rats (64.5±1.0% versus 63.0±1.1%). Sections
stained with Van Gieson’s elastic further showed
increased smooth muscle fibers and collagen in the
OLETF rats, which had a significantly higher ratio of
collagen-stained tissue to total vessel area compared
with LETO rats (Figure 4); this change in the small
vessels of both LETO rats (28.6±1.8% versus
27.8±1.5%) and OLETF rats (48.5±1.7% versus
45.9±1.9%) was not improved by cilostazol at
168hours after 2VO.
Numerous TUNEL-positive cells, with darkly
stained nuclei or nuclear fragments and cytoplasmic
halos characteristic of apoptotic cells, were observed
around the infarct area. As shown in Figure 5, the
frequency of TUNEL-positive cells was greater in
OLETF rats than in LETO rats, and was not reduced
by cilostazol during the 48hours after 2VO
(53.4±1.3% versus 51.3±1.5% at 24hours and
55.2±1.1% versus 52.4±0.8% at 48hours), but
decreased significantly after 96hours (36.3±1.4%
versus 31.3±1.2% at 96hours and 28.3±1.7%
versus 19.5±1.5% at 168hours; P<0.05). By con-
trast, the frequency of TUNEL-positive cells was
significantly reduced by cilostazol in each of the five
LETO rats tested (29.5±1.1% versus 19.5±1.0% at
24hours after 2VO, 31.3±1.3% versus 21.4±1.2% at
48hours, 19.4±1.1% versus 10.3±1.5% at 96hours,
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Figure 3 Infarct volume and rates of TUNEL-, Bax-, and Bcl-2-positive cells. The venous infarct volume was reduced by cilostazol in
the Long-Evans Tokushima Otsuka (LETO) rats. In the Otsuka Long-Evans Tokushima Fatty (OLTEF) rats, the infarct volume
increased up to 48hours after two-vein occlusion (2VO), but was significantly reduced by cilostazol after 96hours. The percentage of
TUNEL-positive cells was higher, but was reduced significantly after 96hours, in the OLETF rats, while it was significantly reduced
by cilostazol in the LETO rats. The percentage of Bax-positive cells showed the same pattern. The percentage of Bcl-2-positive cells
near the infarct area significantly increased 48hours after cilostazol administration in both the LETO and the OLETFrats. The data for
the cilostazol-administered groups are represented by dark bars and the data for the carboxymethyl cellulose (CMC)-administered
groups are represented by light bars. TUNEL, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end
labeling; Bax, B-cell lymphoma 2-associated X protein; Bcl-2, B-cell lymphoma 2.
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P<0.05).
Figure 5 also illustrates the Bax expression near
the infarct area in the cortical tissues. The overall
percentage of cells that was immunopositive for Bax
was higher in OLETF rats than in LETO rats, and was
not reduced by cilostazol during the 48hours after
2VO (52.4±1.1% versus 49.2±1.3% at 24hours and
46.3±1.0% versus 42.5±1.3% at 48hours), but was
reduced significantly at 96hours after 2VO
(35.2±1.2% versus 30.2±1.0% at 96hours and
28.4±1.2% versus 18.9±1.3% at 168hours;
P<0.05). Similar to TUNEL staining, the percentage
of Bax-positive cells was reduced by cilostazol in
each of the five LETO rats tested (30.4±1.2% versus
20.2±1.3% at 24hours after 2VO, 25.4±1.1% versus
15.1±1.0% at 48hours, 20.1±1.2% versus 9.5±
1.3% at 96hours, and 10.5±1.4% versus 5.1±1.2%
at 168hours; P<0.05).
By contrast, Figure 5 shows that there was little
immunolabeling for Bcl-2 near the infarct area at
24hours after 2VO in both LETO rats (5.0±1.2%
versus 7.4±1.4%) and OLETF rats (4.1±1.1%
versus 6.4±1.3%); however, the number of Bcl-2-
positive cells gradually increased over time, and was
significantly increased by cilostazol at 48hours
after 2VO in both LETO rats (6.4±1.2% versus
10.2±1.1% at 48hours, 13.1±1.4% versus
28.8±1.5% at 96hours, and 24.5±1.3% versus
38.7±1.5% at 168hours; P<0.05) and OLETF
rats (5.6±1.2% versus 9.4±1.1% at 48hours,
11.4±1.3% versus 22.3±1.4% at 96hours, and
22.3±1.5% versus 34.5±1.3% at 168hours;
P<0.05).
There were many AGE-positive cells in the OLETF
rats (70.1±5.4% versus 71.4±4.8%) but compara-
tively few in the LETO rats (11.1±6.4% versus
11.4±5.1%) at 168hours after 2VO with vehicle or
cilostazol treatment (Figure 6).
Discussion
We examined the postadministration effects of
cilostazol in a 2VO model. Cilostazol significantly
reduced the infarct size and the number of apoptotic
cells in the area surrounding the infarct 24, 48, 96,
and 168hours after 2VO in the LETO rats. However,
the infarct size was not reduced by cilostazol 24 and
48hours after 2VO in the OLETF rats. The infarct
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Figure 4 Comparison of the composition of cerebral small vessels between Otsuka Long-Evans Tokushima Fatty (OLETF) and Long-
Evans Tokushima Otsuka (LETO) rats using smooth muscle actin (SMA) and Van Gieson’s elastic (VGE) staining. Sections stained
with VGE demonstrated a significantly higher ratio of collagen-stained tissue to total vessel area in OLETF versus LETO rats. This
change in the small vessels of both LETO (28.6±1.8% and 27.8±1.5%) and OLETF (48.5±1.7% and 45.9±1.9%) rats was not
affected by cilostazol (CZL) at 168hours after 2VO. The ratio of wall thickness to luminal area was significantly higher in the OLETF
rats than in the LETO rats. The wall thickness was not improved by CZL at 168hours after 2VO in either LETO (43.3±1.2% versus
42.4±1.4%) or OLETF (64.5±1.0% versus 63.0±1.1%) rats (bar=20mm, 1,000 magnification). The data for the CZL-
administered groups are represented by dark bars and the data for the carboxymethyl cellulose (CMC)-administered groups are
represented by light bars.
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after 2VO, as was the number of apoptotic cells
around the infarct core, in the OLETF rats. Multi-
point measurement detected a beneficial effect of
cilostazol on the ischemic CBF in the area of the
cortex that might be perfused by collaterals (i.e., the
ischemic penumbra). The improvement of the pe-
numbral CBF might have contributed to the reduc-
tion of infarct size in the LETO rats. However, no
CBF improvement was observed in the OLETF rats.
The small-vessel morphology in the cortex was not
changed by cilostazol in either of the rat strains:
cilostazol did not affect the vessel wall thickness and
narrow lumen areas revealed by SMA staining,
the peri-vascular fibrosis and collagen deposition
revealed by Van Gieson’s elastic staining, and the
increased AGE immunolabeling in the OLETF rats
compared with the LETO rats. The extent of venous
infarction and apoptosis was reduced at 24hours
after 2VO in the LETO rats due to the CBF
improvement caused by cilostazol; however, the
presence of lesions was also reduced after 96hours
in the OLETF rats, not as a result of CBF improve-
ment but rather due to the activation of Bcl-2 by
cilostazol.
In the OLETF rats, cilostazol induced a similar
pattern of Bcl-2 expression to that seen in the LETO
rats (in terms of both the timing and the level of
expression); the expression of Bcl-2 might thus have
Figure 5 Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL), Bax, B-cell
lymphoma 2-associated X protein (Bax), and B-cell lymphoma 2 (Bcl-2) staining in the penumbra, and the effects of cilostazol (CZL)
after 96hours in Long-Evans Tokushima Otsuka (LETO) and Otsuka Long-Evans Tokushima Fatty (OLETF) rats. The number of
apoptotic TUNEL-positive cells (with darkly stained nuclei or nuclear fragments with a cytoplasmic halo) was reduced by CZL. Strong
Bax protein expression was observed both in the penumbra and in areas distant from the acute ischemic lesion, and was suppressed
by CZL. Immunolabeling for Bcl-2 near the infarct area was increased by CZL (bar=200mm, 200 magnification). CMC,
carboxymethyl cellulose.
Figure 6 Advanced glycation end product (AGE) staining at
168hours after the administration of cilostazol (CZL) in Long-
Evans Tokushima Otsuka (LETO) and Otsuka Long-Evans
Tokushima Fatty (OLETF) rats. AGEs were strongly
expressed in OLETF rats, and were not suppressed by CZL
(70.1±5.4% versus 71.4±4.8%). AGEs were more weakly
expressed in LETO rats and were also not affected by CZL
(11.1±6.4% versus 11.4±5.1%; bar=200mm, 200
magnification). The data for the CZL-administered groups
are represented by dark bars and the data for the
carboxymethyl cellulose (CMC)-administered groups are repre-
sented by light bars.
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the brain damage induced by the 2VO model.
The efficacy of cilostazol in the 2VO model could
be largely attributable to mechanisms other than
antiplatelet effects.
Venous Ischemia After Two-Vein Occlusion
A previous study confirmed that apoptosis due to
venous ischemia appeared both in the center of the
infarct and in remote areas (Nishioka et al, 2006).
Congestion of the cerebral vein impairs the micro-
circulation in the cortical area, and the gradually
expanding ischemic area further affects the CBF and
unstable brain tissue. The area around the infarct
lesion is at an incomplete ischemic stage, which
might influence the function and condition of
neurons. Venous ischemia, in particular, causes
widespread changes and gradual alterations after
venous occlusion, resulting in extensive apoptosis
(Kempski et al, 1999). Venous ischemic neuronal
death is characterized by cell swelling, and the
inhibition of adenosine triphosphate synthesis oc-
curs with the formation of nitric oxide radicals
leading to necrosis in the infarct core. The circula-
tion in the rat brain differs from that in the human
such that the cortical collateral flow is sufficiently
rich to maintain the CBF in the ischemic state
induced by single vein occlusion (Nakase et al,
1996). However, venous ischemic neuronal death, as
described above, in the normal and diabetic states
can be evaluated in the 2VO model in rats.
A previous study using the 2VO model showed
that the regional CBF between the two occluded
veins had decreased significantly in diabetic OLETF
rats compared with nondiabetic LETO rats by
90minutes after occlusion (Wajima et al, 2010). We
also previously showed that Bax expression in
diabetic animals was further enhanced around the
infarct area, consistent with an increase in apoptotic
activity as indicated by a high degree of TUNEL-
positive staining (Wajima et al, 2010). Our present
study examined whether cilostazol attenuated the
venous ischemic changes and widespread apoptotic
changes around the infarct lesion, as shown in the
MCAO model in rats, and whether these changes
occurred in the diabetic state.
Efficacy of Cilostazol in Nondiabetic Rats
Our results revealed that cilostazol increased the
regional CBF in nondiabetic LETO rats. Increased
CBF in the ischemic region after the administration
of cilostazol was reported previously in an MCAO
model (Ito et al, 2009; Wainwright et al, 2007).
Cilostazol is a selective inhibitor of phosphodiester-
ase-3. On inhibition of phosphodiesterase-3 activity
and suppression of cyclic adenosine monopho-
sphate) degradation, the intracellular cyclic adeno-
sine monophosphate level increased in platelets and
blood vessels, leading to the inhibition of platelet
aggregation and the dilation of vascular smooth
muscle cells. Through these vasodilating effects,
the decrease of regional CBF induced by 2VO seemed
to be rescued by cilostazol in nondiabetic rats.
Recently, cilostazol was shown to have pleiotropic
effects other than antiplatelet and vasodilating
activities (Ito et al, 2009). It inhibited the production
of intracellular reactive oxygen species and apoptotic
cell death in human umbilical vein endothelial cells.
A reduction of oxidative stress by cilostazol might
have contributed to the protection from brain injury
after ischemia (Wainwright et al, 2007). In our
current study, the infarct volume and numbers of
TUNEL- and Bax-positive cells were decreased by
cilostazol in the penumbra around the infarct lesion
in the nondiabetic state. We considered the suppres-
sion of venous ischemic and brain apoptotic changes
by cilostazol to be a dual effect of increasing the CBF
via the dilatation of vessels, and the neuroprotective
and antiinflammatory reactions described above.
Previous reports showed that cilostazol treatment
decreased the brain damage and cell apoptosis
around the lesion after MCAO in rats (Ito et al,
2009; Nonaka et al, 2009).
Regarding the effects on vessels, cilostazol in-
duced nitric oxide production from endothelial
nitric oxide synthase (Wainwright et al, 2007). These
endogenous vasodilating substances are protective in
cerebral ischemic models. We did not confirm the
vasodilating effect of endothelial nitric oxide
synthase in 2VO and in the diabetic state; however,
we believe that it was responsible for increasing the
regional CBF to some extent in 2VO without
changing the morphology of the cortical vessels in
the nondiabetic LETO rats. In our study, the admin-
istration of cilostazol for 7 days did not change the
morphology of small vessels in the cortical area.
However, the regional CBF after 2VO was increased
by cilostazol in the nondiabetic LETO rats. We
attributed this CBF increase to the dilatation of
vessels (i.e., main trunk vessels) other than the small
vessels in the cortical regions.
Limited Efficacy of Cilostazol in Diabetic Rats
Previous studies showed that a combination of
diabetes and MCAO resulted in more severe brain
injury than MCAO alone due to enhanced apoptosis
(Rizk et al, 2006). Previous reports (Lee et al, 2008)
found that cilostazol exerts neuroprotective effects
against transient focal ischemic brain injury. How-
ever, few reports have shown that cilostazol de-
creased the infarction after MCAO in diabetic rats.
In our current study, cilostazol did not improve the
regional CBF improvement during the 4hours after
2VO in diabetic OLETF rats. A previous study
without the administration of cilostazol showed a
greater degree of reduction of the CBF within
ischemic areas in diabetic OLETF rats than in
Cilostazol limits venous infarcts in diabetic rats
D Wajima et al
2038
Journal of Cerebral Blood Flow & Metabolism (2011) 31, 2030–2040nondiabetic LETO rats; this suggested that the
diminished CBF also had a role in the more severe
venous infarction and apoptosis seen in diabetic
subjects (Wajima et al, 2010). Mechanisms that might
explain the decreased regional CBF in the diabetic
state were suggested in a previous study (Duckrow
et al, 1987). The arterial oxygen content, which is
determined in part by Ht, could be an important
determinant of regional CBF. However, the Ht values,
which are a major determinant of blood viscosity, did
not significantly differ between the OLETF and
LETO rats (and were not influenced by cilostazol).
Previous studies have showed increased myogenic
tone in experimental diabetes (Didion et al, 2005;
Dumont et al, 2003). In addition to increased basal
tone, the small cerebral vessels of diabetic rats
exhibit reduced expression of the endothelium-
derived relaxation factor, which might result in
impaired vasodilatation. We predict that these
factors might suppress the vasodilating effects of
cilostazol in the diabetic state. Without an increase of
CBF caused by cilostazol, its administration had no
effect on the infarct volume and number of apoptotic
cells in the early phase (during the 48hours after
administration) in the diabetic state.
Diabetes causes hypertrophic remodeling of the
peripheral vasculature that is characterized by
reduction of the lumen diameter, enlargement of
the tunica media, abnormalities in the expression
and localization of extracellular matrix components,
such as collagen and laminin deposition in vessel
walls and accelerated formation of atherosclerotic
plaques, and intimal proliferation (Vinik and Flem-
mer, 2002). Our current results indicated a loss of
cerebral capillaries and morphological changes of the
smooth muscle within the cerebral cortex vascula-
ture of OLETF rats. We observed thickening of small-
vessel walls and perivascular fibrosis in the OLETF
rats, which are typical cerebral microvascular ather-
osclerotic changes. Cilostazol did not affect these
changes or any of the physiological data in our
experiment. Hence, although a previous report
suggested that cilostazol might improve atherosclero-
tic changes in medium-to-large vessels (Ling et al,
2006), it did not affect those seen in small vessels
over 168hours after administration. Alongside the
diabetic suppression of vasodilating effects induced
by cilostazol, this could explain why its administra-
tion did not increase the regional CBF after 2VO in
diabetic OLETF rats.
AGE cytotoxicity was observed in the diabetic
state. In the late stage of glycation, AGEs are formed
after a complex cascade of repeated dehydration,
condensation, fragmentation, oxidation, and cycliza-
tion reactions, via intermediates such as 3-deoxyglu-
cosone (Kikuchi et al, 2003). Our results were
consistent with previous reports showing increased
AGE-positive immunolabeling in diabetic OLETF
rats compared with nondiabetic LETO rats (Seki
et al, 2003). In addition, due to AGE cytotoxicity,
there were increased lesions and apoptotic changes
in OLETF rats. The numbers of AGE-positive cells
were not reduced by cilostazol. We therefore propose
that cilostazol inhibited the inflammatory responses,
but that the AGE cytotoxicity in neurons progressed
slowly and was not affected. In summary, in the
diabetic state, the extent of ischemic lesions and
apoptotic changes increased after 2VO together with
AGE cytotoxicity, and cilostazol reduced these
changes.
Effects of B-Cell Lymphoma 2 Overexpression Induced
by Cilostazol in Diabetic Rats
Our results suggested that diabetes exacerbated the
neuronal death after cerebral ischemic injury caused
by CBF reduction in areas with small-vessel athero-
sclerotic changes and the induction of apoptosis
caused by AGE cytotoxicity; however, a reduction of
infarct lesions induced by cilostazol via Bcl-2 was
seen over time. In the presence of Bcl-2 overexpres-
sion, the infarct volume and the numbers of TUNEL-
and Bax-positive cells were decreased by cilostazol
in the late phase (i.e., after 96hours).
Recently, cilostazol was shown to suppress the
laddering feature of DNA fragmentation in a rat
MCAO model (Ito et al, 2009). Accumulating evi-
dence points to a significant role during apoptosis of
Bcl-2 and cytochrome c release from mitochondria to
the cytosol, and of caspase-3 activation in promoting
cell survival and death (Chen et al, 2001). The
overexpression of Bcl-2 in transgenic mice protected
neurons from ischemia-induced cell death (Lee et al,
2008). Similarly, human Bcl-2 overexpression with
herpes simplex virus vectors limited neuronal death
in focal cerebral ischemia (Lee et al, 2008). Bcl-2
protects the integrity of mitochondrial dysfunction
induced by cerebral apoptosis stimuli. A previous
study showed that cilostazol treatment resulted in
the overexpression of the phosphorylated cyclic
adenosine monophosphate-responsive element bind-
ing protein and Bcl-2 after hypoperfusion (Lee et al,
2008). This finding suggests that the brain-protective
role of cilostazol might be manifested through its
antiapoptotic effect via the cyclic adenosine mono-
phosphate-responsive element binding protein phos-
phorylation signaling pathway and the subsequent
activation of Bcl-2.
Our current results were consistent with previous
findings (Lee et al, 2008), in that cilostazol induced
the activation of Bcl-2 after 2VO in both strains of rat.
In the diabetic OLETF rats in particular, although the
CBF after 2VO was not increased by cilostazol, the
extent of venous infarction and apoptotic change was
reduced after 168hours. We attributed this to the
activation of Bcl-2 by cilostazol.
Other potential mechanisms for the protective
effect in the penumbral region induced by cilostazol
were reported previously. Cilostazol was reported
to suppress the breakdown of the blood–brain
barrier after focal ischemia, to increase levels of
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responsive element binding protein and cyclooxy-
genase-2, to suppress the activation of microglia and
astrocytes, and to reduce the activation of oligoden-
drocytes, as well as decreasing tumor necrosis factor
(TNF)-a and apoptosis in white-matter lesions in the
bilateral common carotid artery ligation (BCCAL) rat
model (Lee et al, 2008). These factors were not
considered in the present experiment, although some
might be related to the effect of cilostazol on the
expression of Bcl-2.
In conclusion, we showed that cilostazol mini-
mized venous ischemic injury in both diabetic and
control rats. These findings suggest that cilostazol
could be a potential therapeutic drug for use against
diabetes-associated vascular disease, especially
microvascular disease.
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